ClinicalTrials.gg
Active, not recruitingNCT00682513Updated Nov 3, 2026

Studies of the Variable Phenotypic Presentations of Rapid-Onset Dystonia Parkinsonism and Other Movement Disorders

An observational study in Dystonia and Parkinsonism, sponsored by State University of New York at Buffalo. Active, not recruiting at 2 sites in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by State University of New York at Buffalo · Observational

How we know

Updated Nov 3, 2026Now Active, not recruitingNow Recruiting+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Family-based
Time perspective
Prospective
Enrollment
198
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 118 studies in Dystonia with a site in United States — 27 open to participants now, 31 under way, none of them phase 3. Dystonia · United States.

Planned enrollment
15th of 56
198 · median 80
Started
2008
with 5 others
Observational
56 of 118
12 open now
Primary completion
2027-07
later than 6 of 30 live
Registered
25th of 118
by date

Among the 118 studies in Dystonia with a site in United States, this one is the 15th largest by planned enrollment of the 56 observational ones that give a count, is one of 6 that started in 2008, is one of 56 observational ones, reaches primary completion later than 6 of the 30 other live ones, and was the 25th registered.

Dystonia

213 studies on the registry are indexed under Dystonia; 54 are open to participants now.

Browse Dystonia studies →

Open to participants now

27 of the 118 studies in Dystonia with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Dystonia studies recruiting now, 19 (46%) set no upper age limit and 10 (24%) stop at 75 or younger; 18 take children under 18; 6 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Dystonia with a site in United States, or all of them as a file.
02

Study summary

The purposes of this study are to identify persons with rapid-onset dystonia-parkinsonism (RDP) or mutations of the RDP gene, document prevalence of the disease, and map its natural history.

Read the detailed description

Rapid-onset dystonia-parkinsonism (RDP) is a rare, movement disorder with variable characteristics ranging from sudden onset (hours to days) of severe dystonic spasms to gradual onset of writer's cramp. RDP has elements of both dystonia and Parkinson's disease-two neurological diseases with motor and neuropsychological symptoms that hinder the quality of life. An internal trigger associated with extreme physiological stress has been reported prior to abrupt symptom onset of RDP.

This study, which is a continuation of an earlier study begun by Dr. Allison Brashear, aims to more clearly identify the characteristics associated with RDP and to explore whether mutations in the RDP gene are associated with atypical dystonias, Parkinson's disease, and other movement disorders.

The study involves in-person or remote (telemedicine) neurological assessments and blood samples for genetic analysis.

03

Conditions studied

  • Dystonia
  • Parkinsonism

Keywords

  • dystonia
  • parkinsonism
  • rapid-onset dystonia-parkinsonism
  • RDP
  • Alternating Hemiplegia of Childhood
  • AHC
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Selection will take place predominantly via primary care clinics, i.e., physician referrals when patients present with a movement disorder suspicious for RDP.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • clinical presentation consistent with ATP1A3 disease (RDP, AHC) or confirmed diagnosis of RDP or AHC

Exclusion criteria

Exclusion Criteria:

  • none
05

Study design

Observational model
Family-based
Time perspective
Prospective
Enrollment
198 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • ATP1A3 Mutation

    Those with RDP, AHC, unaffected carriers of ATP1A3 mutations, and non-carrying family members

06

What researchers measure

Primary outcomes

  1. RDP Severity

    History of symptom onset and duration will be obtained and current degree of severity assessed.

    Time frame: Visit 1 (baseline)

Secondary outcomes

  1. Presence of neuropsychiatric disease

    Psychiatric interview and cognitive assessment will be performed to examine presence or absence of symptoms.

    Time frame: Will be assessed at Visits 1 (baseline) and 2 (24 months), approximately 2 years apart

07

Study locations

2 sites
08

References and documents

Publications

  • Cook JF, Hill DF, Snively BM, Boggs N, Suerken CK, Haq I, Stacy M, McCall WV, Ozelius LJ, Sweadner KJ, Brashear A. Cognitive impairment in rapid-onset dystonia-parkinsonism. Mov Disord. 2014 Mar;29(3):344-50. doi: 10.1002/mds.25790. Epub 2014 Jan 16. PubMed 24436111 ↗
  • Brashear A, Mink JW, Hill DF, Boggs N, McCall WV, Stacy MA, Snively B, Light LS, Sweadner KJ, Ozelius LJ, Morrison L. ATP1A3 mutations in infants: a new rapid-onset dystonia-Parkinsonism phenotype characterized by motor delay and ataxia. Dev Med Child Neurol. 2012 Nov;54(11):1065-7. doi: 10.1111/j.1469-8749.2012.04421.x. Epub 2012 Aug 28. PubMed 22924536 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Jul 2027 and a completion of Jul 2027. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2008
First posted
May 22, 2008
Start
Apr 2008
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting→Active, not recruiting
changed Oct 28, 2026 · changed Nov 3, 2026
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • University of Miami · Miami, United Statesno status→Recruiting
  • University at Buffalo · Buffalo, United Statesno status→Recruiting
Oct 28, 2026
Eligibility
Minimum age none→6 Years
Nov 3, 2026
Contact
Study contact now listed: added r•••@buffalo.edu · •••7461. See the current contact
Oct 28, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • University of Miami · Miami, United StatesContact added s•••@med.miami.edu · •••3647Contact added (no phone or email listed)
  • University at Buffalo · Buffalo, United StatesContact added r•••@buffalo.edu · •••7461
Oct 28, 2026
Show all 2 updates
  1. Nov 3, 2026
    Recruiting→Active, not recruiting
    Eligibility Minimum age none→6 Years
    + 2 other changes: contact details and site details
  2. Oct 28, 2026
    Active, not recruiting→Recruiting
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • University of Miami · Miami, United Statesno status→Recruiting
    • University at Buffalo · Buffalo, United Statesno status→Recruiting
    Contact Study contact now listed: added r•••@buffalo.edu · •••7461. See the current contact
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • University of Miami · Miami, United StatesContact added s•••@med.miami.edu · •••3647Contact added (no phone or email listed)
    • University at Buffalo · Buffalo, United StatesContact added r•••@buffalo.edu · •••7461
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT00682513
Responsible party
Allison Brashear, MD, MBA (Dean, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo) — Principal investigator
First posted
May 22, 2008
Start date
Apr 2008
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Allison Brashear, MD
principal investigator · Dean, University at Buffalo Jacobs School of Medicine and Biomedical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion